StockData
Eloxx Pharmaceuticals, Inc. logo

Eloxx Pharmaceuticals, Inc. (ELOX) stock

ELOXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$10.41−1.33 (-11.33%)

Close on Nov 18, 2026Market cap $70.68MP/E –Yield –

Eloxx Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Eloxx Pharmaceuticals's operating income for the twelve months ending Dec 31, 2023 was -$17.29M. For fiscal 2025 it was -$6.44M. The highest annual figure on record is -$2.47M in fiscal 2024.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$6.44M–
FY2024Dec 31, 2024-$2.47M–
FY2023Dec 31, 2023-$17.29M–
FY2022Dec 31, 2022-$34.42M–
FY2021Dec 31, 2021-$66.02M–
FY2020Dec 31, 2020-$33.46M–
FY2019Dec 31, 2019-$50.56M–
FY2018Dec 31, 2018-$47.57M–
FY2016Jun 30, 2016-$11.19M–
FY2015Jun 30, 2015-$18.08M–
FY2014Jun 30, 2014-$9.15M–
FY2013Jun 30, 2013-$4.65M–
FY2012Jun 30, 2012-$5.41M–
FY2011Jun 30, 2011-$7.92M–
FY2010Jun 30, 2010-$4.85M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026-$4.45M–
Q1 FY2026CQ1 2026Mar 31, 2026-$3.80M–
Q2 FY2025CQ2 2025Jun 30, 2025-$1.58M–
Q1 FY2025CQ1 2025Mar 31, 2025-$1.22M–
Q4 FY2023CQ4 2023Dec 31, 2023-$4.03M–
Q3 FY2023CQ3 2023Sep 30, 2023-$3.64M–
Q2 FY2023CQ2 2023Jun 30, 2023-$4.14M–
Q1 FY2023CQ1 2023Mar 31, 2023-$5.48M–
Q4 FY2022CQ4 2022Dec 31, 2022-$6.03M–
Q3 FY2022CQ3 2022Sep 30, 2022-$7.14M–
Q2 FY2022CQ2 2022Jun 30, 2022-$10.30M–
Q1 FY2022CQ1 2022Mar 31, 2022-$10.95M–
Q4 FY2021CQ4 2021Dec 31, 2021-$11.63M–
Q3 FY2021CQ3 2021Sep 30, 2021-$10.25M–
Q2 FY2021CQ2 2021Jun 30, 2021-$35.73M–
Q1 FY2021CQ1 2021Mar 31, 2021-$8.41M–
Q4 FY2020CQ4 2020Dec 31, 2020-$5.81M–
Q3 FY2020CQ3 2020Sep 30, 2020-$6.30M–
Q2 FY2020CQ2 2020Jun 30, 2020-$7.59M–
Q1 FY2020CQ1 2020Mar 31, 2020-$13.77M–
Q4 FY2019CQ4 2019Dec 31, 2019-$11.49M–
Q3 FY2019CQ3 2019Sep 30, 2019-$12.78M–
Q2 FY2019CQ2 2019Jun 30, 2019-$14.31M–
Q1 FY2019CQ1 2019Mar 31, 2019-$11.98M–
Q4 FY2018CQ4 2018Dec 31, 2018-$14.11M–
Q3 FY2018CQ3 2018Sep 30, 2018-$11.36M–
Q2 FY2018CQ2 2018Jun 30, 2018-$13.54M–
Q1 FY2018CQ1 2018Mar 31, 2018-$8.55M–
Q4 FY2016CQ2 2016Jun 30, 2016-$1.40M–
Q3 FY2016CQ1 2016Mar 31, 2016-$4.89M–
Q2 FY2016CQ4 2015Dec 31, 2015-$3.76M–
Q1 FY2016CQ3 2015Sep 30, 2015-$1.15M–
Q4 FY2015CQ2 2015Jun 30, 2015-$919.03K–
Q3 FY2015CQ1 2015Mar 31, 2015-$1.22M–
Q2 FY2015CQ4 2014Dec 31, 2014-$10.75M–
Q1 FY2015CQ3 2014Sep 30, 2014-$5.19M–
Q4 FY2014CQ2 2014Jun 30, 2014-$3.68M–
Q3 FY2014CQ1 2014Mar 31, 2014-$2.13M–

More Eloxx Pharmaceuticals figures

See a number that looks wrong?